Quansin Bio: New drug Rucerituzumab monoclonal antibody application for listing accepted

LightningPacketLoss · 2026-03-12T19:49:29+00:00

Quansin Bio's Lucechita monoclonal antibody injection has been accepted by the National Medical Products Administration and is planned for the treatment of adult active ankylosing spondylitis. Based on Phase III clinical trials, the drug has shown significant improvement in patients and has a good safety profile, marking a progress in the company's R&D efforts.

LightningPacketLoss

2026-03-12 19:49:29

Abstract generation in progress

Recently, Quansin Bio announced that the new drug application (NDA) for its self-developed Ruceqita monoclonal antibody injection (anti-IL-17A monoclonal antibody, development code: QX002N) has been accepted by the National Medical Products Administration on March 9, 2026. The drug is classified as a Category 1 biological product for therapeutic use, with acceptance number CXSS2600039, intended for the treatment of adult active ankylosing spondylitis (AS).

This submission is based on a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial. The results showed that Ruceqita monoclonal antibody significantly and sustainably improved disease activity, signs, and symptoms in patients with active AS who had inadequate response or contraindications to NSAIDs. It also demonstrated good safety and tolerability during 52 weeks of treatment and follow-up. Ruceqita monoclonal antibody is the company’s first innovative drug to receive NDA acceptance, marking a step forward in the company’s R&D pipeline.

(Quansin Bio Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.